

VP	YAP	p-YAP	TEAD	AXL	CYR61
0	1.54±0.19	1.67±0.14	2.10±0.37	2.62±0.01	1.21±0.05
4	0.88±0.11**	1.26±0.19*	1.00±0.26**	0.72±0.12***	0.96±0.03**
8	0.62±0.08**	0.99±0.07**	0.56±0.16**	0.44±0.01***	0.65±0.12**
12	0.44±0.11***	0.34±0.09***	0.32±0.09***	0.34±0.03***	0.48±0.10***

MCF-7 BC cells were treated with VP at various concentrations for 72 h, and then subjected to Western blotting for detecting the expression of YAP, p-YAP and TEAD,AXL, CYR61 and CTGF, *P<0.05, **P<0.01, ***P<0.001.

VP	YAP	p-YAP	AXL	CYR61	CTGF	TEAD
0	1.82±0.17	1.14±0.05	1.68±0.20	2.01±0.21	1.28±0.15	1.59±0.14
4	1.45±0.14*	0.98±0.07*	1.07±0.01**	0.80±0.13**	0.97±0.02*	0.95±0.26*
8	0.55±0.06***	0.77±0.06**	0.68±0.05**	0.51±0.17***	0.60±0.06**	0.54±0.15***
12	0.37±0.02***	0.70±0.07**	0.59±0.08***	0.31±0.04***	0.43±0.03***	0.49±0.05***

BT-474 BC cells were treated with VP at various concentrations for 72 h, and then subjected to Western blotting for detecting the expression of YAP, p-YAP and TEAD,AXL, CYR61 and CTGF, *P<0.05, **P<0.01, ***P<0.001.

VP	YAP	p-YAP	AXL	CYR61	CTGF	TEAD
0	1.27±0.13	1.31±0.07	1.94±0.26	1.47±0.12	1.61±0.11	2.17±0.36
4	0.58±0.15**	0.98±0.12*	1.05±0.14**	1.08±0.21*	1.12±0.20*	0.73±0.20**
8	0.45±0.04***	0.46±0.08***	0.43±0.05***	0.71±0.19**	0.76±0.15**	0.48±0.13**
12	0.29±0.03***	0.38±0.06***	0.23±0.03***	0.41±0.06***	0.45±0.02***	0.38±0.04***

BT-549 BC cells were treated with VP at various concentrations for 72 h, and then subjected to Western blotting for detecting the expression of YAP, p-YAP and TEAD,AXL, CYR61 and CTGF, *P<0.05, **P<0.01, ***P<0.001.

VP	Cleaved Caspase-9	Cleaved PARP	BCL-2/BAX	Survivin
0	0.32±0.07	0.21±0.02	4.04±0.14	1.72±0.16
4	0.75±0.06**	0.60±0.08**	1.41±0.22***	0.90±0.07**
8	1.04±0.14**	1.02±0.13***	0.78±0.10***	0.74±0.04***
12	1.60±0.27**	2.28±0.49***	0.20±0.04***	0.25±0.06***

MCF-7 were incubated with vehicle control or verteporfin and then subjected to Western blotting for detecting the expression of Survivin , Bax and Bcl-2, PARP, cleaved PARP, Caspase-9 and

Cleaved Caspase-9,*P<0.05, **P<0.01, ***P<0.001.

VP	Cleaved Caspase-9	Cleaved PARP	BCL-2/BAX	Survivin
0	0.38±0.04	0.24±0.06	3.05±0.25	1.49±0.20
4	0.85±0.20*	0.33±0.12	1.68±0.26**	1.11±0.11*
8	1.15±0.16**	0.43±0.07*	0.78±0.16***	0.86±0.19*
12	1.31±0.16***	2.28±0.29***	0.34±0.06***	0.65±0.09**

BT-474 were incubated with vehicle control or verteporfin and then subjected to Western blotting for detecting the expression of Survivin , Bax and Bcl-2, PARP, cleaved PARP, Caspase-9 and Cleaved Caspase-9,*P<0.05, **P<0.01, ***P<0.001.

VP	Cleaved Caspase-9	Cleaved PARP	BCL-2/BAX	Survivin
0	0.36±0.09	0.33±0.09	2.69±0.17	1.28±0.07
4	0.75±0.15*	0.89±0.15**	1.33±0.35**	0.96±0.07**
8	0.98±0.09**	1.10±0.11***	0.75±0.10***	0.60±0.10***
12	2.72±0.43***	1.78±0.15***	0.38±0.11***	0.40±0.11***

BT-549 were incubated with vehicle control or verteporfin and then subjected to Western blotting for detecting the expression of Survivin , Bax and Bcl-2, PARP, cleaved PARP, Caspase-9 and Cleaved Caspase-9,*P<0.05, **P<0.01, ***P<0.001.